COMPOSITIONS FOR BIOMEDICAL APPLICATIONS

• US 20150209477A1
• Filed: 11/14/2014
• Published: 07/30/2015
• Est. Priority Date: 08/03/2007
• Status: Abandoned Application

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: Lian, Jane B., Li, Xinning, Ayers, David C., Song, Jie
• Application Number:
  US14/541,401
• Publication Number:
  US 20150209477A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/414 Growth factors
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: A61L 27/38 containing added animal cells organs or tissue containing native cells A61L27/36
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/46 with phosphorus-containing inorganic fillers
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: C08G 77/045 containing less than 25 silicon atoms
• CPC Class Codes: C08G 77/38 Polysiloxanes modified by chemical after-treatment C08G77/045 takes precedence
• CPC Class Codes: C08G 77/445 containing polyester sequences

Abstract

The invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. In further embodiments, the polymer matrix comprises biomolecules.

Claims

1-15. -15. (canceled)

16. A method for preparing an elastic composite material loaded with cells or biomolecules, comprising:

a) providing an elastic composite material comprising;

i) a polymer matrix comprising polymethacrylate and ethylene glycol units, wherein the polymethacrylate has side chains comprising hydroxyl groups, and

ii) hydroxyapatite aggregates distributed within said polymer matrix, wherein said composite material is between 10% and 70% by weight hydroxyapatite aggregates within said polymer matrix, wherein said hydroxyapatite aggregates have sizes between 50 nanometers and 50 micrometers;

b) creating pores in said composite material providing an elastic composite material; and

c) mixing said elastic composite material with a component selected from the group consisting of cells and biomolecules providing an elastic composite loaded with said component.

17. The method of claim 16, wherein said cells are bone marrow cells.

18. The method of claim 17, wherein said biomolecule is selected from the group consisting of growth factors, cytokines, and gene vectors.

19. The method of claim 18, wherein said subject is a selected from the group consisting of a human, mouse, rat, dog, cat, rabbit, pig, horse, and ape.

27. The method of claim 16, wherein the elastic composite material is porous.

28. The method of claim 16, wherein the cells are bone marrow stem cells.

29. The method of claim 28, wherein the bone marrow stem cells are mesenchymal stem cells.

30. The method of claim 16, wherein the biomolecule is selected from a recombinant protein or a gene vector encoding the protein.

31. The method of claim 16, wherein the biomolecule is a growth factor.

32. The method of claim 16, wherein the biomolecule is a recombinant bone morphogenetic protein selected from the group consisting of BMP-2 and BMP-2/7.

33. The method of claim 27, wherein the porous elastic composite material retains reversible compressive behavior under a compressive load of 2.6 MPa strains up to 40% when hydrated, and is capable of withstanding a compression force between 150 and 500 MPa without brittle fracture when freeze-dried.

34. The method of claim 16, wherein the polymethacrylate is poly(2-hydroxyethyl methacrylate).

35. The method of claim 16, wherein the composite material is capable of withstanding up to 700 MPa compressive load and up to 90% compressive strain without exhibiting brittle fracture when freeze-dried.

36. The method of claim 16, wherein said hydroxyapatite is polycrystalline.

37. The method of claim 16, further comprising:

d) implanting said loaded composite into a subject.

20-26. -26. (canceled)